Back to Journals » International Journal of Nanomedicine » Volume 6

Effect of 5-aminolevulinic acid-based photodynamic therapy via reactive oxygen species in human cholangiocarcinoma cells

Authors Kim CH, Chung C, Choi KH, Yoo J, Hyung Kim D, Jeong Y, Kang DH

Published 30 June 2011 Volume 2011:6 Pages 1357—1363


Review by Single anonymous peer review

Peer reviewer comments 2

Cy Hyun Kim1,2, Chung-Wook Chung1, Kyung Ha Choi1, Jin-Ju Yoo1, Do Hyung Kim1,2, Young-IL Jeong1, Dae Hwan Kang1,2
1National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea; 2School of Medicine, Pusan National University, Yangsan, Republic of Korea
The first two authors contributed equally to this work.

Abstract: Cancer cells have been reported to exhibit an enhanced capacity for protoporphyrin IX (PpIX) synthesis facilitated by the administration of 5-aminolevulinic acid (ALA). We investigated the effect of ALA-based photodynamic therapy (PDT) on human cholangiocarcinoma cells (HuCC-T1). Since protoporphyrin IX (PpIX), a metabolite of ALA, can produce reactive oxygen species (ROS) under irradiation and then induce phototoxicity, ALA-based PDT is a promising candidate for the treatment of cholangiocarcinoma. When various concentrations of ALA (0.05–2 mM) were used to treat HuCC-T1 cells for 6 or 24 hours, the intracellular PpIX level increased according to the ALA concentration and treatment time. Furthermore, an increased amount of PpIX in HuCC-T1 cells induced increased production of ROS by irradiation, resulting in increased phototoxicity.

Keywords: ALA-based photodynamic therapy, HuCC-T1, protoporphyrin IX, ROS

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.